594 related articles for article (PubMed ID: 9719082)
1. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
2. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
3. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
4. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer.
Meyskens FL; Gerner EW
J Cell Biochem Suppl; 1995; 22():126-31. PubMed ID: 8538189
[TBL] [Abstract][Full Text] [Related]
5. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
7. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
8. Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications.
Thomas T; Thomas TJ
Breast Cancer Res Treat; 1994 Feb; 29(2):189-201. PubMed ID: 8012036
[TBL] [Abstract][Full Text] [Related]
9. Regulation of transglutaminase activity by polyamines in the gastrointestinal mucosa of rats.
Wang JY; Viar MJ; Johnson LR
Proc Soc Exp Biol Med; 1994 Jan; 205(1):20-8. PubMed ID: 7906881
[TBL] [Abstract][Full Text] [Related]
10. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine.
Boyle JO; Meyskens FL; Garewal HS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1992; 1(2):131-5. PubMed ID: 1306095
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of polyamine synthesis induces p53 gene expression but not apoptosis.
Li L; Li J; Rao JN; Li M; Bass BL; Wang JY
Am J Physiol; 1999 Apr; 276(4):C946-54. PubMed ID: 10199827
[TBL] [Abstract][Full Text] [Related]
12. Effects of difluoromethylornithine on proliferation, polyamine content and plating efficiency of cultured human carcinoma cells.
Seidenfeld J
Cancer Chemother Pharmacol; 1985; 15(3):196-202. PubMed ID: 3931927
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of proximal small intestinal mucosal growth by luminal polyamines.
Wang JY; McCormack SA; Viar MJ; Johnson LR
Am J Physiol; 1991 Sep; 261(3 Pt 1):G504-11. PubMed ID: 1716059
[TBL] [Abstract][Full Text] [Related]
14. Mucosal polyamine profile in normal and adapting (hypo and hyperplastic) intestine: effects of DFMO treatment.
Hosomi M; Lirussi F; Stace NH; Vaja S; Murphy GM; Dowling RH
Gut; 1987; 28 Suppl(Suppl):103-7. PubMed ID: 3121452
[TBL] [Abstract][Full Text] [Related]
15. Polyamine depletion delays apoptosis of rat intestinal epithelial cells.
Ray RM; Viar MJ; Yuan Q; Johnson LR
Am J Physiol Cell Physiol; 2000 Mar; 278(3):C480-9. PubMed ID: 10712236
[TBL] [Abstract][Full Text] [Related]
16. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial.
Pendyala L; Creaven PJ; Porter CW
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB activation and susceptibility to apoptosis after polyamine depletion in intestinal epithelial cells.
Li L; Rao JN; Bass BL; Wang JY
Am J Physiol Gastrointest Liver Physiol; 2001 May; 280(5):G992-G1004. PubMed ID: 11292609
[TBL] [Abstract][Full Text] [Related]
18. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
19. Polyamine depletion and growth inhibition in Candida albicans and Candida tropicalis by alpha-difluoromethylornithine and cyclohexylamine.
Pfaller MA; Riley J; Gerarden T
J Med Vet Mycol; 1988 Apr; 26(2):119-26. PubMed ID: 3138402
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.
Bailey HH; Kim K; Verma AK; Sielaff K; Larson PO; Snow S; Lenaghan T; Viner JL; Douglas J; Dreckschmidt NE; Hamielec M; Pomplun M; Sharata HH; Puchalsky D; Berg ER; Havighurst TC; Carbone PP
Cancer Prev Res (Phila); 2010 Jan; 3(1):35-47. PubMed ID: 20051371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
